Long Shot: Revance’s RT002 May Banish Frown Lines for 7 Months
Revance's investigational injectable—RT002—achieves median duration of 7 months, a phase 2 active comparator study now underway.
Revance's investigational injectable—RT002—achieves median duration of 7 months, a phase 2 active comparator study now underway.
Researchers have pioneered a novel method to generate human cartilage in the head and neck region by inducing stem cells to transform into craniofacial cartilage, offering potential solutions for cartilage regeneration and transplantation.